n/a (: n/a)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | 0.00 |
---|---|
% Price Change (last 13 weeks): | -87.50 |
% Price Change (last 26 weeks): | -98.58 |
% Price Change (last 52 weeks): | -99.18 |
% Price Change (year to date): | -100.00 |
Return on Equity (%): | n/a |
---|---|
Return on Assets (%): | -283.33 |
Return on Invested Capital (%): | n/a |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Rebus Holdings, Inc. is a pharmaceutical company engaged in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.
|
n/a
2629 Townsgate Road Suite 215 Westlake Village CA 91361 Phone: 1.818.597.7552 Fax: n/a http://www.inspyrtherapeutics.com |
Earnings (1year) ($): | 0.01 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | -0.16 |
Cash Flow ($): | -0.03 |
Price/Earnings (x): | 0.01 |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 0.00 |
---|---|
Current Ratio (x): | 0.00 |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |